Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Aobiome LLC

Home Clinical Trial Sponsors and OrganizationsAobiome LLC

Aobiome LLC

ACTIVE

125 Cambridgepark Dr Ste 5, 马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.aobiome.comSubsidiary11–50 employeesEstablished: 2013-01-01

Part of AOBiome Therapeutics, Inc.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

11

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2013

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

6

54.5%

Phase 1

3

27.3%

Not Applicable

2

18.2%

Trial Status Distribution

Completed

11

100.0%

Clinical Trials

Trials sponsored by this organization (11)

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

Jun 2020547 participants

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

Dec 201828 participants

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

Jul 2018140 participants

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

Mar 2018313 participants

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

Jan 2018122 participants

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

Sep 201771 participants

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

Nov 2016132 participants

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

Aug 2016372 participants

Page 1 of 2

Approvals

No approval data available

News

Rosacea Therapeutics Pipeline Shows Promise with Emerging Therapies

- Over 25 companies are developing novel rosacea treatments, indicating a robust pipeline. - Key emerging therapies like Epsolay, M 1220, and BMX-010 are expected to significantly impact the rosacea market. - Sol-Gel Technologies and Maruho Co., Ltd. are among the leading companies in developing advanced-stage rosacea drugs. - Recent regulatory approvals, such as Zydus Lifesciences' metronidazole topical cream, offer new treatment options.

On this page

Overview
Clinical Trials11
Approvals
News1

Back to Organizations